✦ LIBER ✦

Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in primary cutaneous B-cell lymphomas: first results of a prospective, monocentre study

✍ Scribed by Maza, Sofiane; Gellrich, Sylke; Assaf, Chalid; Beyer, Marc; Spilker, Laura; Orawa, Helmut; Munz, Dieter L.; Sterry, Wolfram; Steinhoff, Matthias

Book ID: 118203297
Publisher: Informa plc
Year: 2008
Tongue: English
Weight: 454 KB
Volume: 49
Category: Article
ISSN: 1042-8194
DOI: 10.1080/10428190802258923

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Yttrium-90 Ibritumomab Tiuxetan as a Sin

Yttrium-90 Ibritumomab Tiuxetan as a Single Agent in Patients With Pretreated B-Cell Lymphoma: Evaluation of the Long-Term Outcome

✍ Pier Luigi Zinzani; Letizia Gandolfi; Vittorio Stefoni; Stefano Fanti; Mariapaol 📂 Article 📅 2010 🏛 Elsevier 🌐 English ⚖ 183 KB

Phase I study of radioimmunotherapy with

Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate (90Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma

✍ Takashi Watanabe; Shoji Terui; Kuniaki Itoh; Takashi Terauchi; Tadahiko Igarashi 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB

The city of hope experience with novel t

The city of hope experience with novel transplant regimens that incorporate standard and escalated dose 90YTTRIUM ibritumomab tiuxetan (90Y-Zevalin®) radioimmunotherapy (RIT) for autologous stem cell transplantation (ASCT) in patients with B-cell non-Hodgkin’s lymphoma (NHL): targeted intensification without increased toxicity and elimination of total body irradiation (TBI)

✍ A. Nademanee; H. Fung; A. Molina; A. Krishnan; R. Rodriguez; L. Popplewell; R.T. 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 56 KB